Evidence map›Paper›PMID 31564810›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2019

Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging.

Chen Zhang, Xinyu Ling, Yanxiu Guo, Cunzhong Yuan, Hongyan Cheng, Xue Ye, Ruiqiong Ma, Yinli Zhang, Yi Li, Xiaohong Chang and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Recent advances in bioprobes and biolabels based on cyanine dyes.Analytical and bioanalytical chemistry · 2022
    Review
  3. Article
  4. Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Chen ZhangDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Xinyu LingState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Yanxiu GuoDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Cunzhong YuanDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China.
Hongyan ChengDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Xue YeDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Ruiqiong MaDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Yinli ZhangDepartment of Pathology, Peking University People's Hospital, Beijing 100044, China.
Yi LiDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Xiaohong ChangDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Beihua KongDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China.
Tao LiuState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Heng CuiDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Peking University · CNPeking University People's Hospital · CNQilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the imaging potential of a novel near-infrared (NIR) probe conjugated to COC183B2 monoclonal antibodies (MAb) in ovarian cancer (OC).

methodsThe expression of OC183B2 antigen in OC was determined by immunohistochemical (IHC) staining using tissue microarrays with the H-score system and immunofluorescence (IF) staining of tumor cell lines. Imaging probes with the NIR fluorescent dye cyanine 7 (Cy7) conjugated to COC183B2 Mab were chemically engineered. OC183B2-positive human OC cells (SKOV3-Luc) were injected subcutaneously into BALB/c nude mice. Bioluminescent imaging (BLI) was performed to detect tumor location and growth. COC183B2-Cy7 at 1.1, 3.3, 10, or 30 μg were used for

resultsThe expression of OC183B2 with a high H-score was more prevalent in OC tissue than fallopian tube (FT) tissue. Among 417 OC patients, the expression of OC183B2 was significantly correlated with the histological subtype, histological grade, residual tumor size, relapse state and survival status. IF staining demonstrated that COC183B2 specifically expressed in SKOV3 cells but not HeLa cells.

conclusionsCOC183B2 is a good candidate for NIR fluorescence imaging and imaging-guided surgery in OC.

Indexed as

COC183B2 antibodynear-infrared fluorescence imagingovarian cancer

Identifiers

PMID31564810
PMCPMC6736662
OpenAlexW2971669440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.